enGene Therapeutics Inc Dossier - Source-backed chat

enGene Therapeutics Inc

ENGNNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.15

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $2.00Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $134M

Enterprise Value $93M

Shares Outstanding 69M diluted

Next Earnings Date31 Dec 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

enGene Therapeutics Inc. is a clinical-stage genetic medicines company whose primary asset, detalimogene voraplasmid (formerly EG-70), is being evaluated for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The stock experienced an 80% decline in May 2026 following disappointing Phase 2 interim data from its LEGEND trial, which revealed a low 12-month complete response (CR) rate of 25% and a median duration of response of 37.3 weeks. This has created a significant efficacy gap compared to competitors like CG Oncology (cretostimogene) and Johnson & Johnson (TAR-200). However, enGene remains highly capitalized with $285.2 million in cash (representing a cash floor well above its current market capitalization of ~$127 million), creating an asymmetric risk/reward profile. The company is streamlining operations via a 50% workforce reduction to preserve cash while preparing for a pre-BLA meeting with the FDA in 2H 2026 and a potential commercial launch in 2027.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets7 analysts · as of 18 Aug 2026

Low · most bearish analyst$2.00

Mean target$3.29

High · most bullish analyst$5.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$2.0020%

The FDA refuses to file or rejects the BLA for detalimogene due to insufficient 12-month durability (25% CR rate) and consistency concerns highlighted by the lower response rates in newer cohorts (39% CR at any time). Insurers decline coverage, and the surfactant cohort fails to show meaningful improvement, forcing the company to liquidate or pivot its platform.

Base CaseCentral scenario

$3.2955%

Matches the consensus mean

enGene successfully files its BLA in late 2026 or early 2027. The FDA reviews the application with a focus on the high unmet medical need and favorable safety profile, leading to a highly debated approval. Commercial uptake is slow and restricted to patients who cannot tolerate or access more effective but highly toxic or complex competing therapies. The stock trades close to its cash value.

Bull CaseUpside scenario

$5.0025%

The FDA grants approval for detalimogene voraplasmid in 2027 based on its exceptional safety profile, ease of community-based administration, and low rate of progression to muscle-invasive disease (3.2%). Additionally, the newly initiated surfactant (polidocanol) combination cohort demonstrates significantly enhanced durability, restoring confidence in the DDX platform and driving market penetration in community urology clinics.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong balance sheet with $285.2 million in cash, cash equivalents, and marketable securities as of April 30, 2026, providing a runway into 2H 2028.
Highly favorable safety and tolerability profile with no grade >=3 treatment-related adverse events leading to discontinuation, and a low rate of progression to advanced disease (3.2%).
Practical, non-viral formulation designed for easy reconstitution in water and community-clinic administration without complex handling or post-procedural restrictions.
FDA Fast Track and RMAT designations, alongside participation in the FDA's CMC Development and Readiness Pilot (CDRP) program, which may expedite regulatory pathways.

Key Investment Risks

Extreme single-asset dependency on detalimogene voraplasmid, making the company's valuation highly sensitive to binary clinical and regulatory outcomes.
Significant efficacy gap compared to competitors, with detalimogene's 12-month CR rate of 25% lagging far behind CG Oncology's cretostimogene (64.2%) and J&J's TAR-200 (57.4%).
Recent workforce reduction of approximately 50% may disrupt pre-commercial preparation and operational execution.
Risk of FDA rejection or highly restrictive labeling due to durability and reproducibility concerns in the LEGEND trial.

Thesis Invalidation Triggers

FDA refusal to file the BLA or issuance of a Complete Response Letter (CRL) in 2027.
Failure of the polidocanol surfactant cohort to show an improvement in complete response rates or durability.
Cash burn accelerating significantly beyond the projected runway, eroding the company's valuation floor.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.